# QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)

> **NCT07450378** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Heterozygous Familial Hypercholesterolemia (HeFH)

## Interventions

- **DRUG:** QLC7401 Injection
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07450378
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2028-04
- **Final completion:** 2028-07
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2026-03-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07450378

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07450378, "QLC7401 in Participants With Heterozygous Familial Hypercholesterolemia (HeFH)". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07450378. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*